Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.

About a quarter of people risk heart attacks and strokes because they inherited a kind of cholesterol that statin drugs can’t ...

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

EMA orphan drug designation is awarded to drugs intended to treat rare diseases that are life-threatening or chronically ...

Unlocking the Potential of siRNA for Drug Development siRNA therapeutics represent a paradigm shift in targeted drug development by enabling precise gene silencing of disease-causing genes.

--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration’s ...

Rona Therapeutics is always committed to developing the best and first-in-class siRNA drugs with differentiation and innovation to address unmet needs and improve outcome in cardiovascular ...

an experimental drug from the pharmaceutical company Eli Lilly, is a small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)], a genetically inherited risk ...

Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its newest preclinical report exploring the evolving landscape of ...